NEW YORK, New York — September 4, 2025 — Leads & Copy — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) has announced convertible note subscription agreements with SurgCenter principals and existing shareholders, Gregory George and William Gueck, for up to US$50.0 million in unsecured convertible notes.
The funding, available upon shareholder approval, will be used to repay secured lenders and for working capital.
The notes can be converted into Mesoblast shares or ADRs at US$16.25 per ADR, a 26% premium over the Nasdaq closing price and a 29% premium over the ASX closing price. The notes carry a 5% annual coupon.
Investors will receive a US$100,000 commitment fee and, subject to shareholder approval, warrants for 5 million ordinary shares or 500,000 ADRs.
Mesoblast is focused on allogeneic cellular medicines for inflammatory diseases. Its product, Ryoncil, is FDA-approved for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients.
Contact:
Paul Hughes
T: +61 3 9639 6036
Emma Neal
E: emma.neal@allisonworldwide.com
T: +1 603 545 4843
Steve Dabkowski
E: steve@bluedot.net.au
T: +61 419 880 486
Source: Mesoblast Limited
